Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30738251 | 0.90 | CA1 (0.79) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL248400 | 0.90 | CA1 (0.79) | CA1CA2MAPTMEN1KMT2A | |
| SCHEMBL4023394 | 0.88 | KMT2A (0.79) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL4026085 | 0.88 | CA1 (0.69) | CA1CA2MEN1KMT2ACA12 | |
| SCHEMBL6380843 | 0.88 | ALDH1A1 (0.70) | CA1CA2MAPTALDH1A1MEN1 | |
| SCHEMBL6802359 | 0.88 | ALDH1A1 (0.70) | CA1CA2MAPTALDH1A1MEN1 | |
| SCHEMBL4026040 | 0.88 | KMT2A (0.79) | CA1CA2MAPTALDH1A1MEN1 | |
| SCHEMBL29591107 | 0.88 | KMT2A (0.79) | CA1CA2MAPTALDH1A1MEN1 | |
| SCHEMBL6376696 | 0.87 | CA1 (0.67) | CA1CA2MEN1KMT2ACA12 | |
| SCHEMBL3546981 | 0.87 | MAPT (0.72) | CA1CA2MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-1611104-B1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-07-01 | — | — | EP | disclosed |
| CN-100432056-C | Tetrahydroisoquinolinylacetamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-12 | — | — | CN | disclosed |
| CN-100393703-C | 1,2,3,4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-11 | — | — | CN | disclosed |
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-08-10 | — | — | US | disclosed |
| CN-1764647-A | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-26 | — | — | CN | disclosed |
| EP-1611104-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-01-04 | — | — | EP | disclosed |
| EP-1274687-B1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085403-A1 | TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| CN-1416420-A | 1,2,3, 4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2003-05-07 | — | — | CN | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178515-A1 | Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | CA1 466/4885CA2 497/4885MAPT 2015/4885 |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | CA1 2487/4885CA2 1619/4885MAPT 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.